Sabrina H Tsang1, Partha Basu2, Noemi Bender3, Rolando Herrero4, Troy J Kemp5, Aimée R Kreimer1, Martin Müller3, Gitika Panicker6, Michael Pawlita3, Ligia A Pinto5, Joshua N Sampson1, Rengaswamy Sankaranarayanan7, John Schussler8, Peter Sehr9, Monica S Sierra1, Elizabeth R Unger6, Tim Waterboer3, Allan Hildesheim10. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 2. Screening Group, International Agency for Research on Cancer, Lyon, France. 3. Infection, Inflammation & Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica. 5. HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 6. Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA. 7. Research Triangle Institute International, New Delhi, India. 8. Information Management Services, Silver Spring, MD, USA. 9. Infection, Inflammation & Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany; Chemical Biology Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. 10. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: Hildesha@mail.nih.gov.
Abstract
INTRODUCTION: Whether existing serological assays are sufficiently robust to measure the lower antibody levels expected following single-dose HPV vaccination is unknown. METHODS: We evaluated seven assays measuring HPV-16/18 immunological responses overall and by number of doses in 530 serum samples from participants receiving varying doses of Cervarix or Gardasil up to 36-months post-vaccination. Serum was evaluated by simplex (HPV-16 ELISA, HPV-18 ELISA), multiplex (LIA-4, VLP-MIA, M9ELISA, GST-L1), and high-throughput pseudovirion-based neutralization assays (HT-PBNA), and results were compared to the gold standard HPV-16/18 secreted alkaline phosphatase neutralization assay (SEAP-NA). Reproducibility was assessed by the coefficient of variation (CV) and intraclass correlation coefficient (ICC). Percent agreement, Pearson correlation, and weighted-kappa were used to assess validity. Determinants of seronegativity were evaluated by chi-squared test. RESULTS: HPV-16: Seropositivity range was 97.1-99.5% for single dose and 98.8-99.8% overall. CV range was 4.0-18.0% for single dose and 2.9-19.5% overall. ICC range was 0.77-0.99 for single dose and 0.74-0.99 overall. Correlation with SEAP-NA range was 0.43-0.85 for single dose and 0.51-0.90 overall. Weighted-kappa range was 0.34-0.82 for single dose and 0.45-0.84 overall. HPV-18: Seropositivity range was 63.9-94.7% for single dose and 86.2-97.9% overall. CV range was 8.1-18.2% for single dose and 4.6-18.6% overall. ICC range was 0.75-0.99 for single dose and 0.83-0.99 overall. Correlation with SEAP-NA range was 0.31-0.99 for single dose and 0.27-0.96 overall. Weighted-kappa range was 0.35-0.83 for single dose and 0.45-0.84 overall. HPV-16 seronegativity was <5% for all assays. HPV-18 seronegativity range was 5.5-17.3%. For LIA-4 and GST-L1 where the proportion of seronegativity was >10%, the strongest correlates of seronegativity were receiving a single vaccine dose and receiving Gardasil. CONCLUSIONS: These results support the utility of existing serological assays to monitor antibody responses following single-dose HPV vaccination. Published by Elsevier Ltd.
INTRODUCTION: Whether existing serological assays are sufficiently robust to measure the lower antibody levels expected following single-dose HPV vaccination is unknown. METHODS: We evaluated seven assays measuring HPV-16/18 immunological responses overall and by number of doses in 530 serum samples from participants receiving varying doses of Cervarix or Gardasil up to 36-months post-vaccination. Serum was evaluated by simplex (HPV-16 ELISA, HPV-18 ELISA), multiplex (LIA-4, VLP-MIA, M9ELISA, GST-L1), and high-throughput pseudovirion-based neutralization assays (HT-PBNA), and results were compared to the gold standard HPV-16/18 secreted alkaline phosphatase neutralization assay (SEAP-NA). Reproducibility was assessed by the coefficient of variation (CV) and intraclass correlation coefficient (ICC). Percent agreement, Pearson correlation, and weighted-kappa were used to assess validity. Determinants of seronegativity were evaluated by chi-squared test. RESULTS:HPV-16: Seropositivity range was 97.1-99.5% for single dose and 98.8-99.8% overall. CV range was 4.0-18.0% for single dose and 2.9-19.5% overall. ICC range was 0.77-0.99 for single dose and 0.74-0.99 overall. Correlation with SEAP-NA range was 0.43-0.85 for single dose and 0.51-0.90 overall. Weighted-kappa range was 0.34-0.82 for single dose and 0.45-0.84 overall. HPV-18: Seropositivity range was 63.9-94.7% for single dose and 86.2-97.9% overall. CV range was 8.1-18.2% for single dose and 4.6-18.6% overall. ICC range was 0.75-0.99 for single dose and 0.83-0.99 overall. Correlation with SEAP-NA range was 0.31-0.99 for single dose and 0.27-0.96 overall. Weighted-kappa range was 0.35-0.83 for single dose and 0.45-0.84 overall. HPV-16 seronegativity was <5% for all assays. HPV-18 seronegativity range was 5.5-17.3%. For LIA-4 and GST-L1 where the proportion of seronegativity was >10%, the strongest correlates of seronegativity were receiving a single vaccine dose and receiving Gardasil. CONCLUSIONS: These results support the utility of existing serological assays to monitor antibody responses following single-dose HPV vaccination. Published by Elsevier Ltd.
Entities:
Keywords:
Antibody response; Human papillomavirus; Immunogenicity; Vaccine
Authors: Mahboobeh Safaeian; Joshua N Sampson; Yuanji Pan; Carolina Porras; Troy J Kemp; Rolando Herrero; Wim Quint; Leen Jan van Doorn; John Schussler; Douglas R Lowy; John Schiller; Mark T Schiffman; Ana Cecilia Rodriguez; Mitchell H Gail; Allan Hildesheim; Paula Gonzalez; Ligia A Pinto; Aimée R Kreimer Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Darron Brown; Martin Müller; Peter Sehr; Michael Pawlita; Hanna Seitz; Ivonne Rubio; Joseph Antonello; David Radley; Christine Roberts; Alfred Saah Journal: Vaccine Date: 2014-08-19 Impact factor: 3.641
Authors: Aimée R Kreimer; Frank Struyf; Maria Rowena Del Rosario-Raymundo; Allan Hildesheim; S Rachel Skinner; Sholom Wacholder; Suzanne M Garland; Rolando Herrero; Marie-Pierre David; Cosette M Wheeler; Paula González; Silvia Jiménez; Douglas R Lowy; Ligia A Pinto; Caroline Porras; Ana Cecilia Rodriguez; Mahboobeh Safaeian; Mark Schiffman; John T Schiller; John Schussler; Mark E Sherman; F Xavier Bosch; Xavier Castellsague; Archana Chatterjee; Song-Nan Chow; Dominique Descamps; Francisco Diaz-Mitoma; Gary Dubin; Maria Julieta Germar; Diane M Harper; David J M Lewis; Genara Limson; Paulo Naud; Klaus Peters; Willy A J Poppe; Brian Ramjattan; Barbara Romanowski; Jorge Salmeron; Tino F Schwarz; Julio C Teixeira; Wiebren A A Tjalma Journal: Lancet Oncol Date: 2015-06-09 Impact factor: 41.316
Authors: Simon R M Dobson; Shelly McNeil; Marc Dionne; Meena Dawar; Gina Ogilvie; Mel Krajden; Chantal Sauvageau; David W Scheifele; Tobias R Kollmann; Scott A Halperin; Joanne M Langley; Julie A Bettinger; Joel Singer; Deborah Money; Dianne Miller; Monika Naus; Fawziah Marra; Eric Young Journal: JAMA Date: 2013-05-01 Impact factor: 56.272
Authors: Hilary A Robbins; Troy J Kemp; Carolina Porras; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Paula Gonzalez; John Schiller; Douglas Lowy; Sylviane Poncelet; Mark Esser; Katie Matys; Allan Hildesheim; Ligia A Pinto; Rolando Herrero; Mahboobeh Safaeian Journal: Front Oncol Date: 2014-01-13 Impact factor: 6.244
Authors: Aimée R Kreimer; Rolando Herrero; Joshua N Sampson; Carolina Porras; Douglas R Lowy; John T Schiller; Mark Schiffman; Ana Cecilia Rodriguez; Stephen Chanock; Silvia Jimenez; John Schussler; Mitchell H Gail; Mahboobeh Safaeian; Troy J Kemp; Bernal Cortes; Ligia A Pinto; Allan Hildesheim; Paula Gonzalez Journal: Vaccine Date: 2018-02-01 Impact factor: 3.641
Authors: Mark H Einstein; Peter Takacs; Archana Chatterjee; Rhoda S Sperling; Nahida Chakhtoura; Mark M Blatter; Jacob Lalezari; Marie-Pierre David; Lan Lin; Frank Struyf; Gary Dubin Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Kavita Panwar; Anna Godi; Clementina E Cocuzza; Nick Andrews; Jo Southern; Paul Turner; Elizabeth Miller; Simon Beddows Journal: MethodsX Date: 2022-06-25
Authors: Sabrina H Tsang; John T Schiller; Carolina Porras; Troy J Kemp; Rolando Herrero; John Schussler; Monica S Sierra; Bernal Cortes; Allan Hildesheim; Douglas R Lowy; Ana Cecilia Rodríguez; Byron Romero; Nicolas Çuburu; Jaimie Z Shing; Ligia A Pinto; Joshua N Sampson; Aimée R Kreimer Journal: NPJ Vaccines Date: 2022-03-29 Impact factor: 7.344
Authors: Alexander Marin; Ananda Chowdhury; Sarah M Valencia; Athina Zacharia; Reinhard Kirnbauer; Richard B S Roden; Ligia A Pinto; Robert H Shoemaker; Jason D Marshall; Alexander K Andrianov Journal: Nanomedicine Date: 2021-01-18 Impact factor: 5.307